The prognosis for patients with primary vitreoretinal is dismal. The close association of primary vitreoretinal lymphoma with primary central nervous system lymphoma is responsible for high rates of mortality. Traditional treatments consist of systemic chemotherapy and whole-brain radiotherapy. The optimal approach for the treatment of isolated primary vitreoretinal lymphoma is unclear.
Methods
A review of the relevant medical and scientific literature was performed, focusing on the clinical features of primary vitreoretinal lymphoma and the progress made in the management of isolated ocular disease.
Results
Ocular treatment options for primary vitreoretinal lymphoma have recently expanded with the addition of intravitreal chemotherapeutic agents and localized radiation. Based on several retrospective reports, a general shift has been made toward local therapy (eg, orbital radiotherapy, intravitreal chemotherapy) for ocular disease. No prospective, randomized clinical trials yet exist to guide therapy.
Conclusions
Optimal treatment regimens for isolated primary vitreoretinal lymphoma continue to evolve. Further investigations into novel therapies and protocols are needed to decrease recurrence rates, reduce or prevent central nervous system involvement, and improve rates of overall survival.
References
1.
MochizukiM., SinghA.D.Epidemiology and clinical features of intraocular lymphoma.Ocul Immunol Inflamm.2009; 17(2): 69–72.
2.
DavisJ.L.Intraocular lymphoma: a clinical perspective.Eye (Lond).2013; 27(2): 153–162.
3.
CouplandS.E.Molecular pathology of lymphoma.Eye (Lond).2013; 27(2): 180–189.
FrenkelS., HendlerK., SiegalT.Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.Br J Ophthalmol.2008; 92(3): 383–388.
6.
ChanC.C., RubensteinJ.L., CouplandS.E.Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.Oncologist.2011; 16(11): 1589–1599.
McCannK.J., Ashton-KeyM., SmithK.Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development.Blood.2009; 113(19): 4677–4680.
9.
CouplandS.E., LoddenkemperC., SmithJ.R.Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.Invest Ophthalmol Vis Sci.2005; 46(11): 3957–3964.
10.
GrimmS.A., PulidoJ.S., JahnkeK.Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.Ann Oncol.2007; 18(11): 1851–1855.
11.
BehinA., Hoang-XuanK., CarpentierA.F.Primary brain tumours in adults.Lancet.2003; 361(9354): 323–331.
12.
CotéT.R., MannsA., HardyC.R.AIDS/Cancer Study Group. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome.J Natl Cancer Inst.1996; 88(10): 675–679.
13.
HoffmanP.M., McKelvieP., HallA.J.Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes.Eye (Lond).2003; 17(4): 513–521.
14.
JahnkeK., KorfelA., KommJ.Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial.Graefes Arch Clin Exp Ophthalmol.2006; 244(6): 663–669.
15.
FardeauC., LeeC.P., Merle-BéralH.Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma.Am J Ophthalmol.2009; 147(5): 886–894, 894.e881.
16.
CassouxN., GironA., BodaghiB.IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma.Invest Ophthalmol Vis Sci.2007; 48(7): 3253–3259.
17.
CouplandS.E.Vitreous biopsy: specimen preparation and interpretation.Monogr Clin Cytol.2012; 21: 61–71.
KimuraK., UsuiY., GotoH Group JILS. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma.Jpn J Ophthalmol.2012; 56(4): 383–389.
20.
SugitaS., TakaseH., SugamotoY.Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid.Jpn J Ophthalmol.2009; 53(3): 209–214.
21.
WangY., ShenD., WangV.M.Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma.Int J Mol Sci.2011; 12(9): 5684–5697.
22.
ShenD.F., ZhuangZ., LeHoangP.Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma.Ophthalmology.1998; 105(9): 1664–1669.
23.
HormigoA., AbreyL., HeinemannM.H.Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment.Br J Haematol.2004; 126(2): 202–208.
24.
JellingerK., RadaskiewiczT.H., SlowikF.Primary malignant lymphomas of the central nervous system in man.Acta Neuropathol Suppl.1975; (suppl 6): 95–102.
25.
NelsonD.F., MartzK.L., BonnerH.Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.Int J Radiat Oncol Biol Phys.1992; 23(1): 9–17.
26.
SkarinA.T., ZuckermanK.S., PitmanS.W.High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.Blood.1977; 50(6): 1039–1047.
27.
HerrlingerU., SchabetM., BruggerW.German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.Ann Neurol.2002; 51(2): 247–252.
28.
HerrlingerU., KükerW., UhlM.NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.Ann Neurol.2005; 57(6): 843–847.
29.
BatchelorT., CarsonK., O'NeillA.Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.J Clin Oncol.2003; 21(6): 1044–1049.
30.
PelsH., Schmidt-WolfI.G., GlasmacherA.Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.J Clin Oncol.2003; 21(24): 4489–4495.
31.
BaumannM.A., RitchP.S., HandeK.R.Treatment of intraocular lymphoma with high-dose Ara-C.Cancer.1986; 57(7): 1273–1275.
32.
BatchelorT.T., KolakG., CiordiaR.High-dose methotrexate for intraocular lymphoma.Clin Cancer Res.2003; 9(2): 711–715.
33.
JahnkeK., ThielE., BechrakisN.E.Ifosfamide or trofosfamide in patients with intraocular lymphoma.J Neurooncol.2009; 93(2): 213–217.
34.
SandorV., Stark-VancsV., PearsonD.Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.J Clin Oncol.1998; 16(9): 3000–3006.
35.
SoussainC., Merle-BéralH., ReuxI.A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases.Leuk Lymphoma.1996; 23(3-4): 339–345.
36.
SoussainC., Hoang-XuanK., TaillandierL.Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.J Clin Oncol.2008; 26(15): 2512–2518.
37.
de SmetM.D., Stark-VancsV., KohlerD.R.Intraocular levels of methotrexate after intravenous administration.Am J Ophthalmol.1996; 121(4): 442–444.
MargolisL., FraserR., LichterA.The role of radiation therapy in the management of ocular reticulum cell sarcoma.Cancer.1980; 45(4): 688–692.
40.
FineH.A., MayerR.J.Primary central nervous system lymphoma.Ann Intern Med.1993; 119(11): 1093–1104.
41.
FerreriA.J., BlayJ.Y., ReniM.Relevance of intraocular involvement in the management of primary central nervous system lymphomas.Ann Oncol.2002; 13(4): 531–538.
FishburneB.C., WilsonD.J., RosenbaumJ.T.Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma.Arch Ophthalmol.1997; 115(9): 1152–1156.
44.
SenH.N., ChanC.C., ByrnesG.Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma.Ocul Immunol Inflamm.2008; 16(1): 29–33.
45.
de SmetM.D., VancsV.S., KohlerD.Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.Br J Ophthalmol.1999; 83(4): 448–451.
46.
SmithJ.R., RosenbaumJ.T., WilsonD.J.Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.Ophthalmology.2002; 109(9): 1709–1716.
47.
HardwigP.W., PulidoJ.S., BakriS.J.The safety of intraocular methotrexate in silicone-filled eyes.Retina.2008; 28(8): 1082–1086.
48.
IttyS., PulidoJ.S.Rituximab for intraocular lymphoma.Retina.2009; 29(2): 129–132.
49.
HashidaN., OhguroN., NishidaK.Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma.Transl Vis Sci Technol.2012; 1(3): 1.
50.
KitzmannA.S., PulidoJ.S., MohneyB.G.Intraocular use of rituximab.Eye (Lond).2007; 21(12): 1524–1527.
51.
OhguroN., HashidaN., TanoY.Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.Arch Ophthalmol.2008; 126(7): 1002–1003.
52.
PulidoJ.S., BakriS.J., Valyi-NagyT.Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control.Retina.2007; 27(8): 1071–1073.
53.
KimH., CsakyK.G., ChanC.C.The pharmacokinetics of rituximab following an intravitreal injection.Exp Eye Res.2006; 82(5) 760–766.
54.
ChuL.C., EberhartC.G., GrossmanS.A.Epigenetic silencing of multiple genes in primary CNS lymphoma.Int J Cancer.2006; 119(10): 2487–2491.
55.
RiemensA., BrombergJ., TouitouV.Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study.JAMA Ophthalmol.2015; 133(2): 191–197.
56.
BerenbomA., DavilaR.M., LinH.S., etI.Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.Eye (Lond).2007; 21(9): 1198–1201.
57.
StefanovicA., DavisJ., MurrayT.Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience.Br J Haematol.2010; 151(1): 103–106.
58.
GrimmS.A., McCannelC.A., OmuroA.M.Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.Neurology.2008; 71(17): 1355–13601.
